Xaira Therapeutics
This role involves supporting the discovery and development of novel biotherapeutics through hands-on laboratory work and characterization of monoclonal and bi/multispecific antibodies. The position requires expertise in biolayer interferometry (BLI) and surface plasmon resonance (SPR) platforms to determine binding kinetics and affinity. The ideal candidate will contribute to early developability assessments and collaborate with cross-functional teams in a startup environment.
Headquarters
Lafayette, California, United States
Company Size
1-10 employees
Founded
2023
Xaira Therapeutics is a drug discovery and development company that uses artificial intelligence to accelerate the creation of life‑changing medicines. They build computational methods, models, datasets, platforms and disciplined processes to transform drug discovery from an artisanal craft into an engineering discipline with greater certainty and success. Xaira leverages these AI‑driven approaches to generate novel therapeutics aimed at delivering better outcomes for patients in need.
How AI is Driving Drug Discovery: Xaira Therapeutics' Marc Tessier Lavigne
1 month ago
Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell
Jun 17, 2025
Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer
Jul 9, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Xaira Therapeutics.
Reinventing Drug Discovery with AI: Marc Tessier-Lavigne on The Long Run
Nov 12, 2025